This study is a single arm trial with before-after comparison design. Three groups of patients with hypertension will be recruited: not taking antihypertension drugs and having normal renal function, taking antihypertension drugs and having normal renal function, and having abnormal renal function without regards of antihypertension drugs use. Each group includes 30 patients. Based on renal function test, the investigators provide the Manlikang containing potassium chloride to patients with normal renal function, and provide the Manlikang not containing potassium chloride to patients with abnormal renal function. All hypertension patients will use the formula salt with very low sodium (Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks. The primary outcome will be the decrease of patients' systolic blood pressure at the end of the trial.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
43
hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
Maoer Shi community
Chongqing, China
the change of systolic pressure
the change of systolic pressure before and after taking Manlikang
Time frame: baseline and 6 weeks
the change in 24-hour urine sodium
the change of 24-hour urine sodium before and after taking Manlikang
Time frame: baseline and 6 weeks
incidence of reducing antihypertensive drug dose
the incidence of reducing antihypertensive drug dose after taking Manlikang in each group.
Time frame: up to 6 weeks
incidence of reaching the normal blood pressure
blood pressure reaches the standard of systolic pressure\<140mmHg and diastolic pressure\<90mmHg after taking Manlikang.
Time frame: up to 6 weeks
adverse event
the adverse events after taking Manlikang
Time frame: up to 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.